In this whitepaper, explore how human pharmacokinetic data can guide formulation decisions, minimise development risk and help teams select the simplest viable approach for poorly soluble molecules.

Poor solubility becomes a programme-level risk when it creates uncertainty around the chemistry, manufacturing and controls (CMC) pathway and the exposure a formulation will achieve in people. Teams must decide how much formulation complexity to introduce, how much of a limited active pharmaceutical ingredient (API) supply to commit and when the evidence is strong enough to commit to a formulation pathway. Poorly timed decisions can create avoidable development work, consume scarce API and lead to later reformulation and bridging.
A credible strategy starts with the molecule and the exposure the product must achieve. Physicochemical and biopharmaceutic characterisation can narrow the viable options, while API-sparing development allows selected formulations to reach clinical evaluation without producing multiple full-scale batches in advance. Animal models and other preclinical evidence can inform this work, but human pharmacokinetic (PK) data are needed to confirm which formulation should progress.
The preferred route is the simplest formulation capable of achieving the clinical objective and remaining viable through later development. Additional complexity is justified only where it reduces a defined clinical or development risk. This whitepaper examines how Quotient Sciences connects molecule understanding, formulation development and clinical evaluation through Translational Pharmaceutics®. Three case studies show how human PK data supported an advanced enabling formulation, a simpler alternative and progression to a patient-ready dosage form. The paper also considers continuity into potent and later-stage manufacture through Quotient Sciences’ expanding spray-drying and containment capabilities.
Preserve options until human PK supports the decision
Use limited API to reach human evidence sooner, then progress the simplest formulation that achieves the clinical objective.
Section 1. Why poor solubility becomes a programme-level risk
Poor solubility becomes a programme-level risk when it creates uncertainty around the CMC pathway and the exposure a formulation will deliver in people. The risk depends on both the formulation choice and the evidence available when that choice is made, linking CMC strategy directly with clinical interpretation.
1.1 Poor solubility creates uncertainty for CMC strategy and clinical exposure
Poor dissolution or solubility can prevent an orally administered compound from reaching the exposure required for clinical evaluation. Food effects or variable absorption can add uncertainty around dose and dosing conditions, making early clinical findings harder to interpret. Together, these uncertainties affect both formulation strategy and confidence in early clinical decisions.4
- CMC development: Which formulation and manufacturing route should progress?
- Clinical evaluation: Will the formulation provide sufficient and consistent exposure to support interpretation of the emerging data?
These questions are linked. Committing to a formulation before its clinical value is understood can embed unnecessary complexity, while an inadequate formulation can obscure whether disappointing clinical performance reflects the molecule or the exposure achieved. For emerging biotech companies, uncertainty around formulation strategy can also delay key value-inflection milestones, partnering discussions and investment decisions.
Suboptimal early PK can also complicate interpretation of safety and pharmacological findings. If exposure is below or more variable than expected, the programme may not yet have a clear test of the molecule at the intended clinical exposure. That uncertainty can affect the confidence needed for the next dose, formulation or patient-study decision.
1.2 Mistimed formulation decisions create avoidable development work
An early commitment to a complex enabling technology can consume API and require additional processing or stability controls before there is evidence that the complexity is needed. Waiting until poor performance appears in the clinic creates a different problem. Reformulation may then require new manufacturing work, analytical compatibility assessment and clinical bridging before the programme can move forward.
Once clinical batches have been made and a supporting data package established, a technology change may increase scaleup or technology-transfer risk as well as delay the next clinical milestone.”
The cost of changing direction also rises as development progresses. Once clinical batches have been made and a supporting data package established, a technology change may increase scaleup or technology-transfer risk as well as delay the next clinical milestone. The impact can extend beyond early clinical development. A formulation selected without consideration of later-stage manufacturing requirements may require additional process, scale-up or product changes later. For resource-constrained biotech programmes, delays to clinical milestones can also affect fundraising and partnering activity, and broader portfolio decision making. Depending on the programme, additional food-effect, dose or clinical assessments may also be needed to bridge the new product into the existing data package.
Why the timing of the formulation decision matters
Decision made too early
- Premature investment in complex technologies
- Unnecessary API consumption
- Reduced formulation optionality.
- Molecule and product understanding
- API-sparing formulation evaluation
- Human PK confirmation.
- Reformulation delays
- Additional manufacturing and bridging studies
- Increased scale-up and technology-transfer risk.
Decision made while options remain open
Decision made too late
The goal is to preserve flexibility until sufficient evidence supports the formulation choice.
The goal is to preserve meaningful options while the programme can still act on new evidence. Molecule understanding narrows the credible routes, focused formulation assessment tests the strongest candidates and human PK data confirm which option should progress.
Poor solubility creates risk, but formulation decisions create consequences – avoid committing too early, delaying for too long or ignoring the human data needed to guide the decisions.
Section 2. Understanding the molecule and defining the required development outcome
A targeted solubility strategy starts by identifying what may limit exposure and what the eventual product needs to achieve. This prevents technology selection from becoming a platform-first exercise and focuses development on the constraints that matter for the molecule and programme.
2.1 Define what is limiting exposure
Poor exposure may reflect inadequate intrinsic solubility, a dissolution-rate limitation, permeability or gastrointestinal factors. The Developability Classification System can help distinguish dissolution-rate from solubility limitations, while physiologically based pharmacokinetic modelling can explore how dose and formulation changes may affect predicted exposure.1,2 These tools focus on experimental work without confirming which formulation will perform best in people.
2.2 Characterise the drug substance before committing to a route
Solid-state properties can determine which formulation and manufacturing routes are technically credible. Early characterisation should establish the material characteristics most likely to affect dissolution, stability or processing before substantial API is committed, reducing the risk of progressing a material form that later becomes difficult to control or scale. Key characteristics include the following:
- Polymorphism and crystallinity
- Particle size and morphology
- Hygroscopicity
- Thermal and chemical stability.
Understanding these properties early helps avoid investing API in a material form or process that later proves difficult to control or scale. Solid form, crystallinity and particle morphology can also change as a process is optimised or transferred, so the initial formulation strategy must anticipate the properties that may affect dissolution and product performance later.
For highly potent compounds, containment and handling requirements can also influence the practicality of specific formulation and manufacturing routes.”
For highly potent compounds, containment and handling requirements can also influence the practicality of specific formulation and manufacturing routes. Considering these factors early helps avoid selecting development paths that become difficult to implement at scale.
2.3 Define what the clinical product must deliver
The required clinical and product profile determines whether a technically credible formulation is practical for the wider programme. Dose, exposure, available API and potency can constrain the options, while dosage-form requirements, manufacturing scale and cost of goods determine whether the selected route remains viable beyond early clinical evaluation. Key considerations include the following:
- Therapeutic dose and target exposure
- Available API
- Potency and containment requirements
- Intended dosage form
- Expected manufacturing scale and cost of goods.
Together, these inputs establish a focused set of formulation options that can be assessed against the required clinical outcome and the route into later development. This broader view matters when a molecule presents several constraints at once, such as poor solubility alongside limited permeability, high potency or restricted API supply. The formulation route must address the dominant exposure risk without creating a new manufacturing or product constraint.
Section 3. Building a clinically relevant enabling-technology strategy
Technology selection should connect the molecule’s characteristics with the exposure required in people and the route needed for later development. The objective is not to validate an enabling technology or identify the most sophisticated formulation, but to select the simplest formulation capable of delivering the required exposure. Additional complexity is justified where it reduces a defined clinical or development risk.
3.1 Match the formulation route to the molecule and programme need
The information established in Section 2 can narrow development to a small number of credible routes. Particle-size reduction may be suitable where increasing dissolution rate is sufficient. Amorphous solid dispersions can increase apparent solubility, while lipid-based systems may be relevant for highly lipophilic compounds or particular absorption mechanisms.
Technology-specific constraints then help distinguish between viable options. Spray drying can be useful for thermally sensitive molecules but requires a compatible solvent system. Hot-melt extrusion avoids solvents and offers a continuous process, but the drug and excipients must tolerate the processing temperature. Lipid formulations bring separate considerations around drug loading and excipient exposure. Together, these factors distinguish between credible routes without creating a fixed technology hierarchy.
In some programmes, two enabling technologies can produce similar clinical PK. When exposure no longer differentiates them, physical stability, process requirements, cost of goods and the intended manufacturing route become more important. A spray-dried dispersion versus hot-melt extrusion comparison therefore resolves only one part of the wider development decision.
3.2 Select for overall clinical and development viability
The largest in vitro solubility improvement does not by itself identify the strongest development route. The shortlist should also be assessed against the clinical and development requirements that determine whether the route can progress.
- Human exposure: probability of achieving the required human exposure
- API efficiency and physical stability: material use and physical stability
- Process viability: process robustness and cost of goods
- Later-stage suitability: intended dosage form and scale.
Where two technologies are clinically credible, manufacturing requirements, stability and cost may become more important differentiators. Solubility-enhancement technologies can also introduce their own burdens. An amorphous form may require additional physical-stability controls and more involved processing can increase manufacturing requirements. Those burdens are justified where they enable the required clinical performance, but they should be considered before the programme commits to the technology. The preferred route should answer the current clinical question without creating a downstream dead end.
3.3 Know when added complexity is unnecessary
A poorly soluble molecule may still be adequately supported by a simple formulation. Added complexity is justified when it produces a meaningful improvement in exposure or reduces another defined programme risk.”
A poorly soluble molecule may still be adequately supported by a simple formulation. Added complexity is justified when it produces a meaningful improvement in exposure or reduces another defined programme risk. Human data may therefore support a simpler route, as in BOS172767,5 or justify an enabling formulation, as in TQS-168.6 The formulation decision should follow the evidence. Neither outcome should be viewed as inherently preferable; the appropriate decision depends on the molecule, the clinical objective and the resulting human PK profile.
A molecule-led framework for selecting a solubility strategy
1. Define the need
- Exposure constraint
- Target dose
- API and potency
- Intended product.
- Particle-size reduction
- Amorphous solid dispersion
- Lipid-based formulation
- Other molecule-appropriate strategies.
- Human exposure
- API efficiency
- Stability
- Process robustness
- Cost
- Scalability.
2. Narrow credible routes
3. Select for overall viability
Possible outcomes: Simple formulation sufficient | Enabling formulation justified
Select the simplest formulation capable of delivering the required exposure. Introduce complexity only where it reduces a defined clinical or development risk.
Section 4. Using human data to select the clinically relevant formulation
Preclinical data are important for understanding formulation risk, but they cannot confirm how a product will perform in people. Animal models and laboratory assessments may not reliably predict human bioavailability, food effects or relative formulation performance.3 Human PK data are therefore needed to confirm which formulation delivers the required exposure and should progress.
4.1 API-sparing evaluation preserves material and optionality
When API supply is limited, formulation development must generate enough evidence for the next decision without consuming material across every possible technology. A risk-based shortlist and fit-for-phase manufacture allow selected options to reach clinical assessment before the sponsor commits to full-scale batches or long stability programmes for each route.
When API supply is limited, formulation development must generate enough evidence for the next decision without consuming material across every possible technology.”
This approach can accelerate access to decision-enabling human data, reduce API consumption and upfront manufacturing investment, and allow more than one credible formulation strategy to be evaluated while preserving optionality. In one Quotient Sciences formulation-screening programme, selected technologies were manufactured at small scale using tens of grams of API, with stability coverage aligned to the study duration and hundreds, rather than thousands, of dosage units. The exact requirements vary by programme, but the example illustrates how fit-for-phase development can generate comparative human evidence without committing to larger batches or longer stability programmes before the formulation decision is made. These practical benefits may be more important to an early programme than the identity of the formulation technology itself.
Why evaluate at a fit-for-phase scale?
- Earlier human data
- Lower API consumption
- Reduced upfront investment
- Preserved formulation options.
4.2 Human PK data confirm the formulation decision
Head-to-head clinical assessment can show whether a formulation provides the required exposure and whether added complexity delivers a meaningful benefit in people. Depending on the programme, the comparison can also inform food-effect strategy,4 dose and dosing conditions, or subsequent dosage-form development.
The final decision should reflect the human result. An enabling technology may be justified where it materially improves exposure. Where a simpler formulation already meets the clinical objective, further complexity can add cost and development burden without reducing the underlying risk.
- Does the formulation achieve the required exposure?
- Does a more complex technology produce a meaningful clinical benefit?
- Can the selected formulation support the next clinical stage and intended dosage form?
Preclinical evidence informs the development strategy. Human PK data confirm which formulation should progress.
4.3 Translational Pharmaceutics® connects formulation and clinical evidence
Quotient Sciences’ Translational Pharmaceutics platform integrates formulation development, good manufacturing practice (GMP) manufacture and clinical testing so that emerging human data can influence the programme before the formulation pathway is fixed. In many development programmes, these activities occur sequentially across multiple groups or organisations, delaying access to the evidence needed to guide formulation decisions. Integrating them within development allows formulation development, batch manufacture and clinical testing to progress in parallel, keeping flexibility within the decision-making process.
The application depends on where the formulation question arises. During first-in-human development, Translational Pharmaceutics can incorporate phase-appropriate formulation assessment into the clinical programme. Where human PK data already exist and a defined formulation question remains for drug product optimisation, Translational Pharmaceutics can support focused formulation assessment to resolve the remaining formulation question.
By keeping formulation development, manufacture and clinical evaluation closely connected, the programme can respond to emerging PK evidence without a full handoff back into a separate development cycle. Once the lead formulation is selected, the programme can move into development and PK bridging of the intended dosage form.
Which integrated route fits the programme?
Where is the formulation decision being made?
Route 1: Before or during first-in-human development
Translational Pharmaceutics
- Integrate phase-appropriate formulation development, GMP manufacture and clinical testing
- Use emerging human PK data to guide formulation selection.
Route 2: Human PK data are already available
Translational Pharmaceutics
- Compare or optimise selected formulations against a defined clinical question
- Use existing human PK data to support the next formulation decision.
Shared human-data decision
- Human PK confirms the lead formulation
- Select the formulation that delivers the required exposure and supports the next clinical objective.
Next development stage
- Progress to a patient-ready dosage form
- Develop the intended product and use PK bridging to confirm that it retains the required exposure.
Section 5. Progressing from fit-for-phase evaluation to scalable manufacture
An early clinical formulation should answer the immediate PK question without closing off the route to the intended product. Fit-for-phase development allows the programme to defer unnecessary finished-product investment until human evidence supports the lead formulation, while still planning for the dosage form and manufacturing route required later.
5.1 Use fit-for-phase products to answer the immediate clinical question
Before therapeutic dose and clinical performance are understood, developing a finished dosage form for every credible option can consume API and direct investment towards products that may not progress. A powder for reconstitution, suspension or exploratory capsule can provide the flexibility needed for early clinical evaluation, depending on the molecule and study objective.
The early product should still anticipate the intended route where possible. For example, a capsule may use excipients expected in a future tablet, allowing later development to build on established knowledge without completing tablet manufacture before the formulation has been confirmed. Powder-in-bottle or reconstituted products can offer similar flexibility when dose or formulation composition may need to change during early clinical evaluation.
5.2 Develop and bridge the intended dosage form when the evidence supports it
Once emerging human PK data identify the lead formulation, the intended dosage form can be developed while the wider clinical programme continues. Pharmacokinetic bridging then tests whether changes in presentation or processing alter exposure before the later product progresses, with fed and fasted performance or other dosing conditions assessed where relevant to the clinical strategy.
R552 demonstrates this approach.7 A lead spray-dried dispersion was selected from emerging first-in-human PK data, a tablet was developed in parallel and bridged to the powder-in-bottle formulation within the wider programme. The full case is discussed in Section 6.
5.3 Maintain continuity into potent and later-stage manufacture
The selected formulation also needs a credible route through scaleup and later-stage manufacture. Quotient Sciences is expanding its Philadelphia spray-drying capability to support larger-scale PSD1 processing for Phase II and Phase III development, with potential application to suitable lower-volume commercial manufacture. This complements Quotient Sciences’ hot-melt extrusion offering and broadens the available route into later-stage manufacture.
Maintaining continuity within the same organisation can reduce external technology transfer, preserve knowledge generated during formulation selection and reduce vendor complexity as the product moves into later development.”
The PSD1 system is designed for Band 5 containment, with a stated occupational exposure banding capability down to 0.1 µg/m³, alongside contained secondary drying and downstream processing into tablets or capsules. Scaleup still requires attention to variables such as morphology, particle size and process conditions because changes can affect product performance. Maintaining continuity within the same organisation can reduce external technology transfer, preserve knowledge generated during formulation selection and reduce vendor complexity as the product moves into later development.
Section 6. Evidence from integrated solubility programmes
Human PK data can lead to different formulation decisions because the required outcome depends on the molecule and programme. The following case studies show three distinct results: an enabling formulation justified by improved exposure, a simpler product selected after comparison and a formulation selected and bridged to a patient-ready dosage form.
Three programmes. Three formulation decisions.
TQS-168
Development question: Is an enabling formulation required?
Human PK evidence: The spray-dried dispersion achieved four-fold higher exposure than the methylcellulose suspension.
Decision: Progress the spray-dried dispersion.
BOS172767
Development question: Is additional formulation complexity justified?
Human PK evidence: The simpler micronised formulation achieved the required PK performance.
Decision: Progress the micronised formulation.
R552
Development question: Which formulation should progress and how should it be bridged to the intended dosage form?
Human PK evidence: A lead spray-dried dispersion was selected and the tablet achieved comparable exposure to the powder-in-bottle formulation.
Decision: Progress the patient-ready tablet.
6.1 TQS-168: human data justify an enabling formulation
Preclinical studies indicated solubility-limited absorption for TQS-168.6 During the first-in-human single ascending dose study, crystalline API in a methylcellulose suspension was compared with spray-dried dispersion and hot-melt extrusion formulations. The comparison was designed to establish whether an enabling formulation provided a clinically meaningful exposure benefit.
The spray-dried dispersion produced four-fold higher exposure than the methylcellulose suspension and was selected for the remaining cohorts and future patient studies. Food delayed the time to maximum concentration and reduced the maximum concentration, while overall exposure remained similar. Human data therefore provided the evidence to justify the additional formulation complexity.
6.2 BOS172767: human data support the simpler formulation
BOS172767 had already entered Phase I development when poor oral bioavailability and a large food effect created the need for further formulation evaluation before progression into patients.5 Quotient Sciences compared a micronised capsule, a self-emulsifying lipid-based capsule and a spray-dried dispersion tablet to determine whether additional formulation complexity was justified.
The options were assessed in 16 healthy volunteers using fit-for-purpose batch sizes and stability coverage aligned with the clinical study. Human PK data selected the simpler and less costly micronised formulation for further development. The programme moved from formulation start to clinical PK data in six months, showing that the simpler route delivered the required clinical performance.
6.3 R552: formulation selection and patient-ready development proceed together
For R552, physicochemical and nonclinical PK data indicated that an enabling formulation might be required. Flexibility was written into the first-in-human protocol, so alternative formulations could be introduced as data emerged.7 An oral lipid solution and two spray-dried dispersions were evaluated within the programme to identify the formulation that should progress.
One spray-dried dispersion was selected to complete the single ascending dose phase and support multiple ascending dose evaluation. A tablet containing the selected dispersion was developed in parallel and bridged to the powder-in-bottle formulation under fed and fasted conditions. Comparable exposure supported progression of the patient-ready tablet. The overall programme was completed in less than 15 months.
Together, the cases show the same decision principle producing different outcomes. Human PK evidence can justify an enabling technology, confirm that a simpler formulation is sufficient or support progression from an early formulation into the intended dosage form.
Section 7. Making the solubility decision while options remain open
Programme development rarely struggles due to unavailability of formulation technologies. More often, the challenges are caused when development pathways are committed to before sufficient data exists. The strongest solubility strategy preserves flexibility until the available evidence supports commitment. Molecule understanding defines the credible formulation routes. API-sparing development allows those routes to be evaluated without premature full-scale investment, while human PK data confirm which formulation delivers the required exposure and supports the next clinical objective.
That evidence may support an enabling technology or show that a simpler formulation is sufficient. The selected product must also retain a viable path into the intended dosage form and later-stage manufacture. By connecting formulation development, clinical evaluation and downstream product capabilities, Quotient Sciences can support the decision from early risk assessment through progression of the selected formulation.
Discuss your solubility strategy with Quotient Sciences
If poor solubility is creating uncertainty around formulation selection or progression into the clinic, speak to our experts about how an integrated formulation and clinical development strategy could help identify the appropriate next step for your programme.
[Speak to our experts]
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programmes and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Humanity needs solutions, fast.
UK +44 (0)115 974 9000
USA +1-800-769-3518
Email info@quotientsciences.com
Visit www.quotientsciences.com
References
1. Butler JM, Dressman JB. (2010). The developability classification system: Application of biopharmaceutics concepts to formulation development. Journal of Pharmaceutical Sciences, 99(12), 4940–4954. doi:10.1002/jps.22217.
2. Gajewska M, Blumenstein L, Kourentas A, et al. (2020). Physiologically based pharmacokinetic modeling of oral absorption, pH, and food effect in healthy volunteers to drive alpelisib formulation selection. The AAPS Journal, 22(6), 134. doi:10.1208/s12248-020-00511-7.
3. Musther H, Olivares-Morales A, Hatley OJD, et al. (2014). Animal versus human oral drug bioavailability: Do they correlate? European Journal of Pharmaceutical Sciences, 57, 280–291. doi:10.1016/j.ejps.2013.08.018.
4. U.S. Food and Drug Administration. (2026). Assessing the effects of food on drugs in INDs and NDAs: Clinical pharmacology considerations. Guidance for industry.
5. BOS172767: Zann V, McKenzie L, Crowley K, et al. (2023). A Phase I Study Allowing Clinical Screening of Multiple Solubility-Enhancement Formulation Technologies, and an Assessment of Food, PPI and Dose Linearity Assessment with the Selected Formulation of BOS172767, in Healthy Volunteers. Poster presented at the American Association of Pharmaceutical Scientists (AAPS) PharmSci360 Conference. quotientsciences.com Resources.
6. TQS-168: Quotient Sciences. (2026). First-in-Human Assessment of TQS-168: Safety, Tolerability, Pharmacokinetics, and Formulation Selection. quotientsciences.com Resources.
7. Rigel R552: Yan, et al. (2021). Dose and formulation selection during FIH development of R552, a novel RIPk1 inhibitor. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting. quotientsciences.com Resources.”
About the experts

Dr Asma Patel - VP, Global Commercial and Scientific Consulting – Drug Product, Quotient Sciences
Dr Asma Patel is a pharmaceutical development leader with more than 20 years of experience spanning pre-formulation, formulation development, clinical manufacturing and pharmaceutical product strategy across academia, industry and contract development and manufacturing organisations. Her expertise encompasses a broad range of dosage forms and formulation approaches, with a particular focus on addressing bioavailability challenges associated with poorly soluble compounds.
At Quotient Sciences, Dr Patel leads global commercial and scientific consulting activities for drug product development, partnering with biotech and pharmaceutical companies to design phase-appropriate development strategies that balance clinical objectives, manufacturability and long-term programme success. She works closely with clients to guide critical formulation, development and manufacturing decisions from early development through late-stage clinical and commercial programmes.

Robert Cornog - Senior Director, Product Development, Quotient Sciences
Robert Cornog has more than 26 years of experience in product development and process design across a broad range of dosage forms and technologies. His work focuses on applying manufacturing science and risk-based approaches to product development, including the transfer of late-stage and commercial drug product programmes. At Quotient Sciences, he provides technical and scientific support across product development and manufacturing activities.



No comments yet